In Brief: U.S. Bioscience's Ethyol
Executive Summary
U.S. Bioscience's Ethyol: Receives accelerated approval of additional indication for use in patients with non-small cell lung cancer to reduce cumulative renal damage associated with cisplatin chemotherapy. Ethyol (amifostine) was first approved in December to reduce cumulative cisplatin toxicity in patients with advanced ovarian cancer...
|
U.S. Bioscience's Ethyol: Receives accelerated approval of additional indication for use in patients with non-small cell lung cancer to reduce cumulative renal damage associated with cisplatin chemotherapy. Ethyol (amifostine) was first approved in December to reduce cumulative cisplatin toxicity in patients with advanced ovarian cancer.... |